404 results on '"Goldsmith, Kelly"'
Search Results
52. Supplementary Figure 2 from Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma
53. On the Psychology of Scarcity : When Reminders of Resource Scarcity Promote Selfish (and Generous) Behavior
54. Examining the Efficacy of Time Scarcity Marketing Promotions in Online Retail
55. Concurrent myeloid sarcoma, atypical teratoid/rhabdoid tumor, and hypereosinophilia in an infant with a germline SMARCB1 mutation
56. Giving Against the Odds: When Tempting Alternatives Increase Willingness to Donate
57. Ownership: A Perennial Prize or a Fading Goal? A Curation, Framework, and Agenda for Future Research.
58. Children's Oncology Group's 2023 blueprint for research: Neuroblastoma.
59. Scarcity Marketing
60. Online Time Scarcity Promotion Reason
61. When Guilt Begets Pleasure: The Positive Effect of a Negative Emotion
62. The Importance of the Context in Brand Extension: How Pictures and Comparisons Shift Consumers' Focus from Fit to Quality
63. A 3D Bioprinted in vitro Model of Neuroblastoma Recapitulates Dynamic Tumor‐Endothelial Cell Interactions Contributing to Solid Tumor Aggressive Behavior (Adv. Sci. 23/2022)
64. Bringing Our Values to the Table: Political Ideology, Food Waste, and Overconsumption
65. Abstract 1674: FGF8 as a modulator of Wilms' tumor in vitro growth and longevity
66. Phase I study of 131I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.
67. Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study.
68. Can Uncertainty Improve Promotions?
69. Author Correction: Identification of donor microbe species that colonize and persist long term in the recipient after fecal transplant for recurrent Clostridium difficile
70. Identification of donor microbe species that colonize and persist long term in the recipient after fecal transplant for recurrent Clostridium difficile
71. Reinforcement versus balance response in sequential choice
72. Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials
73. sj-pdf-1-mrj-10.1177_00222437221118856 - Supplemental material for Examining the Efficacy of Time Scarcity Marketing Promotions in Online Retail
74. Targeting TRIP13 in Wilms Tumor with Nuclear Export Inhibitors
75. Looking Back and Looking Forward: (Re)Interpreting Consumer Insights in a Time of Transition
76. Identification and Targeting of Protein Tyrosine Kinase 7 (PTK7) as an Immunotherapy Candidate for Neuroblastoma Cellular Therapy
77. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium
78. A New Player in Neuroblastoma: YAP and Its Role in the Neuroblastoma Microenvironment
79. The Dirty Underbelly of Prosocial Behavior: Reconceptualizing Greater Good as an Ecosystem with Unintended Consequences
80. When Does Intoxication Help or Hurt My Case? The Role of Emotionality in the Use of Intoxication as a Discounting Cue
81. Abstract 3034: Proteomic profiling identifies PTK7 as a novel immunotherapeutic candidate for neuroblastoma
82. Abstract 1547: Defining the optimal source of allogeneic γ δ T cells for novel cellular therapy approaches in neuroblastoma
83. High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells
84. High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells
85. Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance
86. Negativity Bias and Task Motivation: Testing the Effectiveness of Positively Versus Negatively Framed Incentives
87. Contributors
88. Renal Neoplasms
89. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)
90. A View from Inside: Insights on Consumer Behavior during a Global Pandemic
91. YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma
92. Scarcity and Consumer Decision Making: Is Scarcity a Mindset, a Threat, a Reference Point, or a Journey?
93. Unobserved altruism: How self-signaling motivations and social benefits shape willingness to donate.
94. The first report of pediatric patients with solid tumors treated with venetoclax.
95. Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.
96. A phase I study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
97. Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.
98. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma
99. Multidisciplinary Care of Adult Wilms’ Tumor During Pregnancy: A Case Report and Review of the Literature
100. When Does Altruism Trump Self-Interest? The Moderating Role of Affect in Extrinsic Incentives
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.